{"name":"Tibotec, Inc","slug":"tibotec-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"TMC125, Darunavir; Ritonavir","genericName":"TMC125, Darunavir; Ritonavir","slug":"tmc125-darunavir-ritonavir","indication":"Treatment of HIV-1 infection in treatment-experienced adult patients","status":"phase_3"},{"name":"emtricitabine [FTC]/tenofovir [TDF]","genericName":"emtricitabine [FTC]/tenofovir [TDF]","slug":"emtricitabine-ftc-tenofovir-tdf","indication":"HIV-1 infection (as part of combination antiretroviral therapy)","status":"marketed"}]}],"pipeline":[{"name":"TMC125, Darunavir; Ritonavir","genericName":"TMC125, Darunavir; Ritonavir","slug":"tmc125-darunavir-ritonavir","phase":"phase_3","mechanism":"TMC125, Darunavir; Ritonavir is a combination of HIV protease inhibitors that work by blocking the protease enzyme, preventing the maturation of viral particles.","indications":["Treatment of HIV-1 infection in treatment-experienced adult patients","Treatment of HIV-1 infection in treatment-naive adult patients"],"catalyst":""},{"name":"emtricitabine [FTC]/tenofovir [TDF]","genericName":"emtricitabine [FTC]/tenofovir [TDF]","slug":"emtricitabine-ftc-tenofovir-tdf","phase":"marketed","mechanism":"This combination of two nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection (as part of combination antiretroviral therapy)","HIV-1 pre-exposure prophylaxis (PrEP)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxObERhU1VZbWFIa2NRTnZMTVNPSk1HSjd1Nk5MMEV2RUJkc0NiejdXSXBNd1M2aFViUG5YRzFRdktqbEtjMklTT25JMWlSVDlhV2ZaSXBRWDBDeW1aVk5WTEZQeUQ5Y1pnanpLX0hGSGh1czltemFaSzlUa2k2OTJxQ1A5NHZnTDA1MzF2UVRLZ01tSldZdlJQUkZn?oc=5","date":"2023-07-30","type":"pipeline","source":"MBA Skool","summary":"Top 10 Conglomerates in USA 2016 - MBA Skool","headline":"Top 10 Conglomerates in USA 2016","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxONHl4V1lhSk04YVg1cHpkZDVoT2hiUFVjYWRialIzNlhDMmZRMFJtamJqY1V6SUpoTWlNdGZ5UEk5VFZJVU4zS1EzS1l1dDFoOXE4ck1RQ2ZhZ1NXNWRtZnNDMFh1SkVMejdaSVV2ZnNFZXBCMUotYXliVFoyNVViRUo1VGR4NHJpNGlNbllJZw?oc=5","date":"2022-01-27","type":"pipeline","source":"BioPharma Dive","summary":"Paul Stoffels, J&J’s former top scientist, to lead Galapagos - BioPharma Dive","headline":"Paul Stoffels, J&J’s former top scientist, to lead Galapagos","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQSEd2VXdRU2NoUS1UbnBmNDVPVVhfbmV2c2tRd05NbHdaTnJXQ3VOM3NIX21kTWhZaVRHZlVRWlVWUjM4eVBqenI3TUx2X2hOSlllRkZBRk5rVkJJeFZzZkNJWDhFbC1DS1FsczdtcGNQSTg1M3N5SGIwYnJVV1l6UTYtSGRhRDIySWc?oc=5","date":"2020-08-05","type":"pipeline","source":"PharmTech.com","summary":"Excipients in Polymeric Drug Delivery and Formulations - PharmTech.com","headline":"Excipients in Polymeric Drug Delivery and Formulations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNaEFxOEtabG9tT0NZLUs2QVdJWERkOWdjNDZiNXVsNWtXYlpZanJ4S2VxUEQxNHhDa0hkbmJZY1NVbVdYd2Y0ekhuX3RsX0luV1hZSTVSd253bmJOS25nWnQxcWtZV2txRzN2aWRYZlBqdUdTenhIa3lUNmhHb05TV1BYbDM4WjQ3MHEzeWJHdzduUG8tNGdYUE14UERUeUM0QVRHTkliMGdIUQ?oc=5","date":"2019-12-10","type":"pipeline","source":"statnews.com","summary":"Do large pharma companies provide drug development innovation? Our analysis says no - statnews.com","headline":"Do large pharma companies provide drug development innovation? Our analysis says no","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFB4dEFWNU5hUThxdGxialJuZVFFN3FJX2hhWlBvQlVqWkFIbnd4VjJlYXp4QU12SVBmdG5qd1Ezal9zR3VmdEg0V25FWU9sQzZZbWo3WjRsMnNVRHZpRTVPcEJaelI4ZFU2TlNIZTdYSTVVMDR1?oc=5","date":"2015-01-02","type":"trial","source":"Clinical Trials Arena","summary":"Incivek / Telaprevir – Treatment for Chronic Hepatitis C - Clinical Trials Arena","headline":"Incivek / Telaprevir – Treatment for Chronic Hepatitis C","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2014-03-20","type":"patent","source":"Mint","summary":"Merck HIV drug strategy in India seen shielding patent - Mint","headline":"Merck HIV drug strategy in India seen shielding patent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQWJUNVo4YWNDaU8tMmoxVlpCeDNvYkRxWlJ1RzQ1WHdCSExnWVotMEI5elF0eGxLaWt3ZHZlWi1ZR3F0bEZTSzBlczUyS0l2endCMWJmSUYxdENZeFBzLWxDR0JfMEhKc1JUdU9XUUVOSHM3T0h0SHlPUEg5NUlGNkhtb09DQ3QyTFhJ?oc=5","date":"2014-03-03","type":"pipeline","source":"Life Science Leader","summary":"Paul Stoffels Expands The Janssen Legacy - Life Science Leader","headline":"Paul Stoffels Expands The Janssen Legacy","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}